Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Negative equity NBB
More debt than assets in 1 of the last 4 fiscal years.
-
Tight liquidity NBB
Cash and receivables cover 5 % of short-term debt in 2025; threshold 65 %.
-
Shrinking team NBB
FTE fell two years in a row, from 6.5 to 2.6.
-
Figures corrected NBB
Corrected annual account filed for 2025.
Financials
Financial year 2025
MEDECO from Kontich, company number BE0879130202, closed financial year 2025 with a result of € -5.8 million after tax. For that financial year MEDECO recorded revenue of € 5.7 million and equity of € -2.7 million. Compared with financial year 2024, the result moved from € 728,400 to € -5.8 million. The company made a loss. More debts than assets. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on September 14, 2026.
€ -2.7 million
▼ € 5.8 million vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ -5.8 million
▼ still € 728,400 profit in 2024
Profit after tax over the fiscal year.
€ 81,463
▼ 80% vs 2024
Cash and bank balances on the last day of the fiscal year.
Loss, nothing to pay out
Reserves fell to € -7.7 million.
People and assets in 2025
2.6
▼ 1.9 vs 2024
Average over the fiscal year, from the social balance sheet.
€ 339,716
▼ 57% vs 2024
€ 130,700 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
Debts at end 2025
€ 21 million
▼ 11% vs 2024
Loans from banks and other lenders, long and short.
€ 764,685
▲ 12% vs 2024
Supplier invoices still open on the last day of the fiscal year. Pays suppliers within 50 days on average.
€ 708,243
▲ 106% vs 2024
Taxes, VAT and social contributions still to pay.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Revenue | € 6,247,436 | € 6,583,312 | € 7,153,955 | € 5,720,108 | ▼ 20% |
| Profit after taxes | € -490,333 | € -4,017,561 | € 728,400 | € -5,808,000 | ▼ € 6.5 million |
| Equity | € 6,441,662 | € 2,424,101 | € 3,152,500 | € -2,655,500 | ▼ € 5.8 million |
| Total debts | € 21,809,334 | € 24,217,864 | € 24,719,827 | € 23,874,109 | ▼ 3% |
| Cash | € 1,959,639 | € 29,842 | € 409,710 | € 81,463 | ▼ 80% |
| Retained profit | € 1,380,162 | € -2,637,399 | € -1,909,000 | € -7,717,000 | ▼ € 5.8 million |
| Bank debt | € 21,000,000 | € 21,263,377 | € 23,476,789 | € 21,000,000 | ▼ 11% |
| Balance sheet total | € 28,250,996 | € 26,641,964 | € 27,872,327 | € 21,218,609 | ▼ 24% |
| Employees (FTE) | 7 | 6.5 | 4.5 | 2.6 | ▼ 1.9 |
Key figures of MEDECO, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to MEDECO?
What happened at MEDECO in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- Julie Steyt stepped down as director. NBB
- Mediq Nederland BV stepped down as director. NBB
- Corrected annual accounts filed for financial year 2025. filed late Source: NBB ↗
- Julie Steyt became a director. NBB
- Mediq Nederland BV became a director. NBB
- New establishment in Kontich. KBO
- Start of the company according to the CBE. KBO
In short
From € 490,333 loss in 2022 to € 5.8 million loss in 2025.
Paid € 840,704 in corporate taxes since 2022.
Best year ever: 2024, with € 728,400 profit.
Pays suppliers within 50 days on average.
A new publication or filing at MEDECO? We notify you, reason included.
Follow MEDECODatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
The shares are held by Mediq International BV (100%). It owns 100% of Remedus BV itself.
Directors
According to the 2025 annual accounts
Mediq Nederland BV
Director · represented by Marcia Luijendijk
since 2017 · until 2029
since 2024 · until 2030
Shareholders
Mediq International BV
100%
Participations
100%
Establishments
Establishment units
Physical locations of this company
Satenrozen 19
2550 Kontich
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 1 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Website
Technologies
Hosting & Email
Email provider
Microsoft 365
Hosting
COMBELL-AS, BE
Website info
Features
Security
Network
Details
- Company number
- 0879.130.202
- VAT number
- BE 0879.130.202
- Registered office
- Satenrozen 19, 2550 Kontich
- Names & denominations
- MEDECO
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 3 February 2006
- Peppol
- Active · Active since 27 Mar 2026
- Contact
- remedus.be
- Activities · NACE
Groothandel in farmaceutische en medische artikelen
Groothandel in farmaceutische producten